Immunomodulatory effect of hypertonic saline in hemorrhagic shock by unknown
REVIEW ARTICLE Open Access
Immunomodulatory effect of hypertonic
saline in hemorrhagic shock
Javad Motaharinia1, Farhad Etezadi2, Azadeh Moghaddas1 and Mojtaba Mojtahedzadeh1*
Abstract
Multiple organ dysfunction syndrome (MODS) and nosocomial infection following trauma-hemorrhage are among
the most important causes of mortality in hemorrhagic shock patients. Dysregulation of the immune system plays a
central role in MODS and a fluid having an immunomodulatory effect could be advantageous in hemorrhagic
shock resuscitation. Hypertonic saline (HS) is widely used as a resuscitation fluid in trauma-hemorrhagic patients.
Besides having beneficial effects on the hemodynamic parameters, HS has modulatory effects on various functions
of immune cells such as degranulation, adhesion molecules and cytokines expression, as well as reactive oxygen
species production. This article reviews clinical evidence for decreased organ failure and mortality in hemorrhagic
shock patients resuscitated with HS. Despite promising results in animal models, results from pre-hospital and
emergency department administration in human studies did not show improvement in survival, organ failure, or a
reduction in nosocomial infection by HS resuscitation. Further post hoc analysis showed some benefit from HS
resuscitation for severely-injured patients, those who received more than ten units of blood by transfusion, patients
who underwent surgery, and victims of traumatic brain injury. Several reasons are suggested to explain the
differences between clinical and animal models.
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Introduction
Multiple organ dysfunction syndrome (MODS) and noso-
comial infection following trauma-hemorrhage are the
most common causes of mortality in hemorrhagic shock
patients [1]. The most important pathogenic mechanism
underlying MODS is disproportionate excitation and dys-
regulation of systemic inflammatory response triggered by
injury and microbial invasion. Although fluid resuscitation
is the mainstay of therapy in hemorrhagic shock, reperfu-
sion of ischemic tissues produces additional injury known
as ischemia reperfusion injury (IRI) [2].
Hypertonic saline (HS) now is widely used as a resus-
citation fluid during critical illness because of its benefi-
cial hemodynamic properties, such as rapid expansion of
intravascular volume, reduction of endothelial and tissue
edema that improves microcirculation, improvement of
blood viscosity caused by hemodilution, and increased
myocardial contractility [3, 4].
Besides the improvement in hemodynamic parameters,
studies on hemorrhagic shock models have shown that
HS can reduce organ failure [5–8]. Recently, new findings
have suggested that HS modulates local and systemic in-
flammatory response [9–16]. It is demonstrated that an
increase of 10 to 20 mOsm/kg in plasma osmolality
caused by HS can affect some functions of immune cells
such as degranulation [10, 14], reactive oxygen species
(ROS) production [10, 14, 17], adhesion molecules expres-
sion [15], cytokine production [18, 19], and phagocytic
ability [12]. However, recent studies showed that some
immunomodulatory effects of HS such as inhibition of
b2 integrin expression on neutrophil surface and alter-
ation in inflammatory cytokine production mediated
via sodium- or chloride-dependent events rather than
by its osmolality [16, 20].
Activation of the innate immune system and inflam-
matory responses are associated with IRI [2, 21]. The
beneficial effects of HS can be partly explained by its
ability to suppress the various functions of neutrophil
including adhesion molecule expression, release of proteo-
lytic enzymes, and production of ROS [10, 13]. Endothelial
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cells (ECs) activation increases the adherence of neu-
trophils promoting capillary congestion and the no-
reflow phenomenon [22]. By inhibiting the Intercellular
adhesion molecule-1 and b2 integrin upregulation, HS
decreases neutrophil rolling and adherence to ECs,
thereby improving microcirculation and vascular per-
meability [23–25]. Reactive oxygen species production
during reperfusion of ischemic tissues is thought to be
the main reason for uncontrolled oxidative stress [21].
Several models of hemorrhagic shock and IRI demon-
strated that HS attenuates oxidative stress by decreasing
inducible nitric oxide synthase expression and increasing
heme oxygenase −1 expression [26–28].
Although the beneficial effects of HS and its immu-
nomodulatory mechanisms have been demonstrated in
experimental studies of hemorrhagic shock, resuscita-
tion with HS has failed to improve patient outcomes in
human studies. Several meta-analyses and review arti-
cles have concluded that there is insufficient evidence
for improved survival of hemorrhagic shock patients re-
suscitated using HS; however, these are dated [29–31].
More recent and larger clinical studies have been per-
formed and, as for the earlier clinical studies, these
trials have provided conflicting results.
This article reviews clinical evidence for decreased
organ failure and mortality in hemorrhagic shock pa-
tients resuscitated with HS, and proposes reasons for
the discrepancy between results of experimental studies
and clinical trials.
Methods
Materials for this review were obtained by searching
PubMed, CINAHL, Scopus, Cochrane Central Register of
Controlled Trials, and Cochrane Database of Systematic
Reviews. Keywords used as search terms were hypertonic
saline, hypertonic solution, hypertonic NaCl, hemorrhagic
shock, trauma, inflammation, anti-inflammatory, multiple
organ failure syndrome, lung injury, and mortality. The
search was limited to publications from 1990 to the
present.
Randomized controlled trials that compared HS with
or without dextran to isotonic crystalloid solutions were
assessed for the study endpoints of patient survival and
organ failure. Papers that assessed HS resuscitation for
concomitant hemorrhagic shock and traumatic brain in-
jury (TBI) were excluded. Only English language articles
were assessed in this review.
HS resuscitation in clinical studies of hemorrhagic shock
To date, several randomized clinical trials (RCT) have
been conducted on hemorrhagic shock. Only 11 RCTs
met the criteria mentioned in the method [32–42]. In
most, trauma patients with hypotension were included
and randomly allocated for treatment with hypertonic
solutions (7.5 % HS (HS7.5 %) and dextran 70 (HSD) or
isotonic crystalloid solutions in pre-hospital settings or
in emergency departments. All trials were prospective
and double-blind and subjects received the same 250 ml
dose of either HS or isotonic crystalloid solution. Resus-
citation was continued by isotonic crystalloid solutions
when needed.
Four of the 11 trials were designed for emergency
departments [33, 34, 37, 40], the others for pre-
hospital settings. In six trials only HSD was used as the
HS [32, 33, 35, 36, 40, 41]; in the others, both HS and
HSD were applied [34, 37–39, 42]. Unfortunately, most
of these studies were conducted prior to 2000; hence,
authors assessed only early mortality and hemodynamic
variables as end points and did not report secondary end-
points such as the development of acute respiratory
distress syndrome (ARDS) or MODS. These studies also
did not report the pretreatment acid–base status of the
patients. Early and late mortality as primary outcomes and
MODS and infection as secondary outcomes were re-
ported in only four studies [35, 40–42].
Table 1 shows that, in the 11 trials assessing more than
2530 cases, results showed that a small volume of HSD
or HS improved hemodynamic variables such as blood
pressure and cardiac output. Importantly, nearly all con-
firmed that the use of HSD or HS was safe and effective
for trauma patients.
Results from evaluating trials were not able to show any
survival improvement; only Younes et al. demonstrated in
1997 that HSD treatment significantly improved survival
after 24 h of resuscitation [40]. In other studies, post hoc
sub-group analysis suggests that certain populations could
be more likely to benefit from HS; these included patients
with TBI, with low mean arterial pressure (MAP), who re-
quired massive transfusions, or underwent surgery.
Younes et al. studied 212 hypovolemic shock patients in
an emergency department. Patients were randomly
assigned for treatment with a 250 ml bolus of 7.5 % HS +
6 % dextran (HSD, n = 101) or 0.9 % normal saline (NS, n
= 111) and resuscitation was followed using a standard al-
gorithm [40]. The groups were assessed at 24 h and
30 days of survival and prognostic factors such as sex, age,
cause of hypovolemia induction, revised trauma score,
Glasgow index, and MAP on admission were evaluated.
The results showed that the 24 h survival rate was signifi-
cantly higher for the HSD group (87 %) than the NS group
(72 %) (p ≤ 0.007). Multivariate analysis showed that RTS
and MAP were independent predictors for 24 h survival
for the HSD group. HSD improved the long-term survival
rate significantly only in the patients with MAP values of
<70 mmHg (p < .01). The overall rate of complications
(renal failure, ARDS, heart failure, infections, and neuro-
logical complications) were similar for both groups (24 %).
The authors concluded that the administration of HS as
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[32] 20 pre-hospital trauma patients
with SBP≤ 100 mmHg
HSD or LR Survival to hospital discharge
and hemodynamic variables
Improved SBP and overall survival rate.
[33] 32 trauma patients with a SBP
< 80 mm Hg admitted to ED
HSD or LR Survival to hospital discharge
and hemodynamic variables
There were no differences in survival rate.
[34] 106 trauma patients with SBP
<80 mm Hg for 6 % HSD or < 90
mmHg for HS and were 18 years
or older admitted to ED
HS or HSD or
LR
Survival to hospital discharge
and hemodynamic variables
There were no differences in overall survival
between any of the groups.
[35] 422 pre-hospital trauma patients
≥ 16 years with SBP≤ 90 mmHg
72 % of participants had sustained
penetrating trauma
HSD or LR Primary end points included:
survival at 24 h and 30 days
(if possible). Secondary end
points included: complications
and safety of HSD
In the HSD 6 % group which requiring
surgery: there was a significant treatment
effect in favor of HSD 6 % (p = 0.02). This
effect was significant in those patients
sustaining penetrating trauma (p = 0.01),
but not in those with blunt trauma.
[36] 166 pre-hospital trauma patients
with SBP≤ 90 mmHg
HSD or LR Survival to hospital discharge
and hemodynamic variables
There was no difference in overall survival
and there is a trend to improve survival
in patients with severe head injuries.
[37] 105 trauma patients≥ 18 years
with SBP < 80 mm Hg admitted to ED
HSD or HS or
NS
Survival to hospital discharge,
hemodynamic variables
There were no significant differences in
overall complication and mortality rates
in the three groups.
[38] 194 pre-hospital trauma patients
with SBP < 90 mm
HSD or HS or
LR
Survival to hospital discharge,
hemodynamics variables, MTOS
and neurological outcome scores
Overall survival in the four treatment
groups was not statistically significant.
Survival in the hypertonic group, however,
was significantly higher than that predicted
by the MTOS norms. The survival rate in
the HS group was higher than that in the
LR group for the cohort with baseline
Glasgow Coma Scale scores of 8 or less
(P < .05 by logistic regression and P < .01
by Cox proportional-hazards analysis)
[39] 258 pre-hospital trauma patients
with SBP < 90 mm Hg.
HSD or HS or
NS
Survival to hospital discharge,
hemodynamics variables, MTOS
and neurological outcome scores
There were no differences in overall survival.
Improved survival vs. predicted MTOS in
high-risk HS & HSD 6 % patients, HS patient
with GCS 8 or less and HSD 6 % patients
with unobtainable BP at the time of
randomization.
[40] 212 hypovolemic shock patients
admitted to ED
HSD or NS Survival at 24 h and 30 days and
complications
The 24 h survival rate was significantly
higher in HSD 6 % (87 %) compared with
NS (72 %) (P < .007). HSD 6 % improved long
term survival rate significantly only in the
patients with MAP < 70 mmHg (p < .01).
[41] 209 pre-hospital blunt trauma
patients with SBP ≤90 mm Hg
“The study was stopped for futility
after the second interim analyses.”
HSD or LR Primary outcome was 28 day
ARDS-free survival. Secondary
outcome; nosocomial infection,
multiple organ failure syndrome
There was no significant difference in
ARDS-free survival. There was an improved
in ARDS-free survival in the patients (19 %
of the population) requiring 10 U or more
of packed RBC in the first 24 h. (HR, 2.18;







with SBP≤ 70 mm Hg or
SBP ≈ 71–90 mm Hg with HR equal
or higher than 108 beats per minute.
(62 % of patients were with blunt trauma.) .
“The study was stopped early (23 % of
proposed sample size) for futility and
potential safety concern.”
HSD or HS or
NS
Primary outcome was 28 day
survival. Secondary outcomes
included: fluid and blood
requirements in the first 24 h,
physiologic parameters of organ




There was no significant difference in 28
day survival between treatment groups.
There was a higher mortality for the
post-randomization subgroup of patients
who did not receive blood transfusions in
the first 24 h, who received hypertonic
fluids compared to NS (P < 0.01).
There were no differences between groups
in organ failure or nosocomial infections.
HSD dextran 70 in HS. HS hypertonic saline 7.5 %. NS 0.9 % saline. LR ringer’s lactate. SBP systolic blood pressure. MAP mean arterial pressure. MTOS major trauma
outcome study. BP blood pressure. RTS revised trauma score. ARDS acute respiratory distress syndrome. CI confidence interval. HR hazard ratio. RBC red blood
cells. HR heart rate. RCT randomized clinical study. ED emergency department
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an initial treatment of hypovolemic patients admitted
through the emergency department is safe and associated
with a beneficial outcomes. Further study is needed to
identify the survival benefits in patients treated with HS in
a pre-hospital setting.
Vassar et al. could not prove differences in survival be-
tween differently resuscitated patients in a pre-hospital
setting [38]. They resuscitated injured patients with a
systolic blood pressure (SBP) of <90 mmHg using four
solutions (n = 150 in each group) containing 250 ml of
lactated Ringer’s (LR), 7.5 % HS, 7.5 % sodium chloride
+ 6 % dextran 70, or 7.5 % sodium chloride + 12 % dex-
tran 70 followed by conventional isotonic solutions as
needed. There was no overall difference in survival be-
tween groups, but actual survival in the hypertonic
group was significantly higher than that predicted by
Major trauma outcome study (MTOS) norms. The sur-
vival rate in the HS group was higher than that in the
LR group for patients with baseline Glasgow Coma Scale
scores of ≤ 8 (p < 0.05 by logistic regression; p < 0.01 by
Cox proportional hazards analysis). The authors con-
cluded that infusion of a small volume of 7.5 % HS early
in resuscitation was safe and improved the survival rates
of severely-injured patients when compared with MTOS
norms. The addition of dextran to hypertonic solution
showed no benefits.
Prior this study, in 1991, Vassar et al. published the re-
sults of 166 pre-hospital trauma patients recording SBP ≤
90 mmHg [36]. They resuscitated patients with 250 ml of
either 7.5 % HSD (n = 83) or LR solution (n = 83). Al-
though the results of this study showed no difference in
overall survival between HSD and LR patients, it did show
a trend of improved survival in patients with severe head
injuries. Administration of small volumes of HSD before
hospitalization increased the blood pressure of severely in-
jured patients more effectively than did LR solution and
tended to improve survival in patients with severe head
injuries.
Mattox et al. randomly assigned hypovolemic shock
patients to be administered with HSD or isotonic crys-
talloid solution (LR, NS, plasmalyte) [35]. Survival at
24 h and 30 days (if possible) were primary end points
and improvement in 24 h physiological status, reduction
in post-injury complications, and safety of HSD solu-
tions (in the volume given) with regard to seizures, ana-
phylactoid reactions, and coagulopathies were secondary
end points. The authors estimated that 700 patients
would be required to show a difference in survival, but
only 422 patients were enrolled. Seventy-two percent of
participants had sustained penetrating trauma. HSD has
improved survival significantly in the subpopulation of
patients requiring surgery (p = 0.02). This effect was sig-
nificant in those patients sustaining penetrating trauma
(p = 0.01), but not in those with blunt trauma. Only 22
patients were followed for as long as 30 days. Thus, ana-
lysis was not performed.
The HSD group had fewer complications such as
ARDS, renal failure, sepsis, pneumonia, and coagulopa-
thy than the standard treatment group (7 versus 24).
HSD related coagulopathy, anaphylactoid reactions, and
seizures were not reported. The authors concluded that
bolus administration of 250 ml of 7.5 % HSD is safe and
was as effective as standard resuscitation solutions in the
pre-hospital management of traumatic hypotension. HSD
may also offer a potential benefit in a subgroup of patients
with penetrating injuries, active hemorrhage, or those re-
quiring urgent laparotomy or thoracotomy. Studies with
larger sample sizes will be required to establish which sub-
groups of trauma patients will maximally benefit from
pre-hospital use of a small volume of HS [35].
Lack of conclusive evidence led to meta-analysis to re-
evaluate the effect of HSD on early mortality (24 h sur-
vival). The first was performed by Wade et al. in 1997.
They included eight RCT of trauma patients treated with
HSD until that date and demonstrated that HSD admin-
istrated as the initial fluid therapy enhanced survival of
patients with hypotension caused by trauma (OR = 1.46;
95 % CL; 1.01–2.12). All included studies in this meta-
analysis have been summarized in the present article.
Further improvement in survival was found in patients
with penetrating trauma requiring surgery (OR = 1.97;
1.07–3.61) or blood transfusion. The authors concluded
that initial fluid therapy with HSD was beneficial in pa-
tients requiring blood transfusion, surgery, or patients
with penetrating injuries who required surgery [29].
The second meta-analysis examined eight double-blind
RCTs in which HSD and HS were compared with isotonic
solution [32–39] and also compared HS and isotonic solu-
tion in two trials for the treatment of hypovolemic trauma
patients (These studies was not reviewed in the present
article due to unpublished data). Analysis was done on
615 patients who were treated with 6 % HSD and 340 who
were treated with HS. The primary end point was 30 day
survival after injury or until discharge. Results showed that
the survival rate did not differ for HS and isotonic resusci-
tation (p = 0.46; OR = 0.98; 95 % CI; 0.71–1.36). The
authors concluded that there is a trend toward superiority
of 6 % HSD for improved survival, but it was not signifi-
cant. The results of the meta-analysis showed that resusci-
tation with HS alone did not demonstrate efficacy for
survival of trauma patients with hypovolemia [30].
Bunn et al. conducted meta-analysis in 2004 to deter-
mine whether HS decreases mortality in hypovolemic
patients with and without head injury [31]. Most of the
17 trials (869 participants) included in the analysis had
small precipitants and only five trials conducted on
trauma patients were judged to provide adequate quality
[32–39] (Nine of the studies that have been included in
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this meta-analysis was not reviewed in the present article
due to unpublished data and included TBI patients). The
authors concluded that there was insufficient data to
support efficacy of HS in resuscitation of patients with
trauma, burns, or those who underwent surgery. They
stated that further large and qualified trials were needed
to adequately compare hypertonic and isotonic crystalloid.
Bulgar et al. in 2008 designed a RCT to evaluate ef-
fect of HS on late mortality, multiple organ failure, and
nosocomial infection in blunt traumatic injury with
hypovolemic shock. In this study, 209 patients with SBP
of ≤ 90 mmHg were randomized to receive either HSD
(n = 110) or LR (n = 99) in a pre-hospital setting. The
primary outcome was 28 day ARDS-free survival and
the secondary outcomes were nosocomial infection,
MODS, resource utilization, mortality, and noninfec-
tious complications. There was no significant difference
in ARDS-free survival (adjusted hazard ratio = 1.01;
95 % confidence interval (CI); 0.63–1.60); however,
there was evidence of improvement in ARDS-free sur-
vival by patients (19 % of the population) requiring 10
units or more of packed red blood cells in the first
24 h. (Odds ratio (OR) = 2.18; 95 % CI; 1.09–4.36). Fur-
ther evaluation using Cox proportional hazards
methods to assess the effect of treatment by red cells
transfused again reached the same hazard ratio for
28 day survival (2.49; 95 % CI; 1.1–5.6). There were no
significant differences in the secondary outcome mea-
sures. The authors concluded that although there were
no significant differences in ARDS-free survival and
secondary outcomes, there was a survival benefit in the
subgroup of patients at highest risk for ARDS, such as
those requiring 10 units or more of packed red blood
cells in the first 24 h [41].
Bulger et al. in 2011 conducted a larger trial on trau-
matic hemorrhagic shock in patients. The resuscitation
outcome consortium (ROC) trial was a randomized,
double-blind, multicenter study. Two series of patients
were included; those who recorded SBP ≤ 70 mmHg and
those with heart rates (HR) of ≤ 108 beats per minute
and SBP of 71 to 90 mmHg. Patients randomly received
a 250 ml bolus of HSD, HS, or NS followed by additional
crystalloid as determined by medical requirements in a
pre-hospital setting. The primary outcome was 28 day
survival and the secondary outcomes were incidence of
ARDS, multi-organ failure, infection, number of ventila-
tor days, and physiological and functional outcomes in
the first 28 days after intervention. Because only 23 % of
the proposed sample size was achieved and because of
the increase in mortality among patients receiving no
blood transfusions in the first 24 h, the Data Safety
Monitoring Board halted the study prematurely. The
28 day mortality rates did not differ between HS, HSD
and NS groups (74.5 % HSD (absolute difference in
28 day survival probabilities = 0.1; 95 % CI;−7.5 to 7.8),
73.0 % HS (−1.4; 95 % CI,−8.7 to 6.0), and 74.4 % NS
(p = 0.91). The rate of organ failure or nosocomial in-
fections in patients treated with NS was higher than
those in the HS and HSD groups, but these differences
were not statistically significant. The authors concluded
that initial resuscitation with hypertonic solution in a
pre-hospital setting did not improve 28 day survival.
Future studies are warranted to better define the use of
these fluids in a pre-hospital setting [42].
The Colloids versus Crystalloids for the Resuscitation
of the Critically Ill (CRISTAL) trial enrolled 2857 inten-
sive care unit patients admitted for hypovolemic shock
to evaluate a possible decrease in mortality for the use
of fluid resuscitation with colloids (n = 1443) versus crys-
talloids (1414). No difference in 28 day mortality was
noted, but 90 day mortality improved in those resusci-
tated with colloids (30.7 % vs. 34.2 %). Patients receiving
colloids also recorded more days free of vasopressor
therapy and mechanical ventilation at 7 and 28 days,
respectively. The incidence of organ failure did not differ
between groups; however, the population of this study
was heterogeneous (sepsis, trauma, others cases of
hypovolemic shock) and differed from the previously
discussed trials, which exclusively examined traumatic
hemorrhagic shock patients. Patients in the crystalloid
and colloid groups mainly received isotonic solutions
(96 %) and hydroxylethyl starch (69 %), respectively.
Subgroup analysis was not performed to compare hyper-
tonic saline resuscitation versus isotonic crystalloids or
colloids [43].
Discussion
Bolus administration of HS is safe and effective and im-
proved hemodynamic states from hemorrhagic hypotensive
states [29–31]. In clinical studies, it has been shown that a
bolus of 4 ml/kg of 7.5 % HS can enhance plasma sodium
and osmolality from 147 to 154 mEq/l and 10 to
20 mOsm/kg, respectively; however, the increase in osmo-
lality is temporary and starts to decline after 30 to 60 min
[38–41]. This temporary increase in plasma osmolality can
affect some functions of the immune system, which can
persist for up to 24 h after HS administration [10, 42].
The immunomodulatory effects of hypertonic saline
have clinical significance and include a reduction in the
incidence of acute lung injury and infectious complica-
tions following hemorrhagic shock. Animal studies have
shown that HS decreased acute lung injury and improved
survival [5–8]; however, evidence that HS benefits survival
in hemorrhagic shock patients is inconclusive.
The timing of HS administration appears to be critical.
It has been shown that delayed administration of HS ex-
acerbates the inflammatory response and tissue damage
following trauma [44, 45]. A septic shock model study
Motaharinia et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:47 Page 5 of 8
showed that the beneficial effects of HS diminished if it
is administered after isotonic resuscitation [46]. The re-
sults of experimental and clinical studies indicate that
the best time to administer HS to prevent inflammatory
side effects is early during resuscitation in a pre-hospital
setting. The results of pre-hospital resuscitation in clin-
ical studies showed no significant effect on survival or
improvement in outcome.
Several reasons for the disagreement between results
from animal studies and clinical settings have been pro-
posed. First, the amount and duration of HS infusion
used in clinical studies could have been insufficient to
decrease the inflammatory response in humans. Al-
though the experimental studies in human showed anti-
inflammatory effects of HS [10, 13], because of low sample
size of these studies, it could not be concluded that HS
can produce clinically relevant anti-inflammatory effects
in every traumatic patient.
Another reason for disagreement may be the differ-
ence in model design. Animals were resuscitated using
either HS or isotonic crystalloids immediately after
blood withdrawal [5–8]. In clinical studies under real
conditions, resuscitation may be delayed and isotonic
fluid administration continued after hypertonic treat-
ment. Evidence suggests that fluid resuscitation with
isotonic solutions potentiate neutrophil activation asso-
ciated with increased organ damage [11, 47, 48]. It has
also been demonstrated that hypervolemia alone or
massive resuscitation in trauma patients increases the
risk of ARDS and mortality [49, 50]. It appears that iso-
tonic resuscitation following HS administration attenu-
ates the protective effects of HS on tissue injury and
subsequent MODS.
Another matter for debate is whether trauma patients
included in clinical studies actually had experienced IRI
or had severe inflammatory conditions for which HS
could be beneficial because HS only benefits a subpopu-
lation who require more blood transfusions, have been
severely injured, or require surgery. In these populations,
severe inflammatory processes are generated in response
to trauma. In these situations, the anti-inflammatory
effect of hypertonic saline could be apparent.
Some patients could have existing metabolic acidosis at
the time of treatment. Crystalloid fluids containing high
chloride ion concentrations cause hyperchloremic meta-
bolic acidosis [51]. Metabolic acidosis caused by lactate
accumulation gradually disappears in hemorrhagic shock
patients if tissue perfusion is restored, but the effect of HS
resuscitation on acid–base status is not easily predictable.
Moon et al. [52] showed that HS infusion in hemorrhagic
shock models produces immediate and transient meta-
bolic acidosis by increasing the plasma chloride concen-
tration relative to the plasma sodium concentration.
Metabolic acidosis affects some aspects of the immune
system, increasing neutrophil phagocytosis, intracellular
death, cytokines, ROS production, complement activation,
and impairing leukocyte chemotaxis [53]. Metabolic acid-
osis is also associated with gut barrier dysfunction and
may increase oxidative stress [54]. It is likely that hyper-
chloremic acidosis caused by administration of HS
increases acidosis in already acidotic patients. Acidic
conditions, particularly hyperchloremic acidosis, inhibit
or weaken the immunomodulatory effects of HS and
must be considered at the time of treatment.
Conclusion
Hypertonic saline is safe when used as a resuscitation
fluid in the early phase of trauma/hemorrhagic shock.
Animal studies have demonstrated some benefit for sur-
vival rates, but clinical trials have failed to support such
results in humans. HS has been advantageous for pa-
tients experiencing severe injury and requiring massive
blood transfusions or surgery and in patients with TBI.
Evidence suggests that these patients might experience a
significant inflammatory response which can be amelio-
rated by the anti-inflammatory effects of HS.
The present study suggests that further clinical trials
with large sample sizes be undertaken to clarify which
subgroup of trauma/shock patents gain the most advan-
tage from HS resuscitation. New clinical trials should be
designed to better quantify the clinical benefits of continu-
ing resuscitation after administration of the first HS bolus.
It is also necessary to consider the acid–base status of a
patient before administration of HS solution because the
high chloride content of HS may worsen pre-existing lac-
tic acidosis from superimposed hyperchloremic acidosis.
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